<?xml version="1.0" encoding="UTF-8"?>
<eudamedExport entity="devices">
  <row>
    <udiDi>06974501890047</udiDi>
    <basicUdiDi>69745018900A000101UB</basicUdiDi>
    <tradeName>NovoCyte  Flow Cytometer</tradeName>
    <deviceName>NovoCyte Flow Cytometer</deviceName>
    <manufacturerName>Agilent Biosciences (Hangzhou) Co., Ltd.</manufacturerName>
    <manufacturerSrn>CN-MF-000013066</manufacturerSrn>
    <authorisedRepresentativeName>Agilent Technologies Denmark ApS</authorisedRepresentativeName>
    <authorisedRepresentativeSrn>DK-AR-000001443</authorisedRepresentativeSrn>
    <riskClass>IVD Sınıf A</riskClass>
    <legislation>IVDR 2017/746</legislation>
    <emdnCode>W02020499</emdnCode>
    <emdnDescription>FLOW CYTOMETRY INSTRUMENTS - OTHER</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>K2609-64000, K2609AA</reference>
    <placedOnMarketCountry>Denmark</placedOnMarketCountry>
    <lastUpdated>2026-07-02T13:20:45.008Z</lastUpdated>
  </row>
  <row>
    <udiDi>06974501890665</udiDi>
    <basicUdiDi>69745018900C000401VU</basicUdiDi>
    <tradeName>06974501890665</tradeName>
    <deviceName></deviceName>
    <manufacturerName>Agilent Biosciences (Hangzhou) Co., Ltd.</manufacturerName>
    <manufacturerSrn>CN-MF-000013066</manufacturerSrn>
    <authorisedRepresentativeName>Agilent Technologies Denmark ApS</authorisedRepresentativeName>
    <authorisedRepresentativeSrn>DK-AR-000001443</authorisedRepresentativeSrn>
    <riskClass>IVD Sınıf C</riskClass>
    <legislation>UNKNOWN</legislation>
    <emdnCode>W0103080105</emdnCode>
    <emdnDescription>ANTIBODIES FOR SUBTYPING OF LEUKEMIA (EXCEPT B-&amp;T-CELL TYPING)</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>8921015CE</reference>
    <placedOnMarketCountry>Germany</placedOnMarketCountry>
    <lastUpdated>2026-07-02T13:20:31.245Z</lastUpdated>
  </row>
  <row>
    <udiDi>06974501891419</udiDi>
    <basicUdiDi>69745018900C004301WK</basicUdiDi>
    <tradeName>06974501891419</tradeName>
    <deviceName></deviceName>
    <manufacturerName>Agilent Biosciences (Hangzhou) Co., Ltd.</manufacturerName>
    <manufacturerSrn>CN-MF-000013066</manufacturerSrn>
    <authorisedRepresentativeName>Agilent Technologies Denmark ApS</authorisedRepresentativeName>
    <authorisedRepresentativeSrn>DK-AR-000001443</authorisedRepresentativeSrn>
    <riskClass>IVD Sınıf C</riskClass>
    <legislation>UNKNOWN</legislation>
    <emdnCode>W0103080105</emdnCode>
    <emdnDescription>ANTIBODIES FOR SUBTYPING OF LEUKEMIA (EXCEPT B-&amp;T-CELL TYPING)</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>8930086CE</reference>
    <placedOnMarketCountry>Germany</placedOnMarketCountry>
    <lastUpdated>2026-06-30T09:28:16.303Z</lastUpdated>
  </row>
  <row>
    <udiDi>06974501891396</udiDi>
    <basicUdiDi>69745018900C004201WE</basicUdiDi>
    <tradeName>06974501891396</tradeName>
    <deviceName></deviceName>
    <manufacturerName>Agilent Biosciences (Hangzhou) Co., Ltd.</manufacturerName>
    <manufacturerSrn>CN-MF-000013066</manufacturerSrn>
    <authorisedRepresentativeName>Agilent Technologies Denmark ApS</authorisedRepresentativeName>
    <authorisedRepresentativeSrn>DK-AR-000001443</authorisedRepresentativeSrn>
    <riskClass>IVD Sınıf C</riskClass>
    <legislation>UNKNOWN</legislation>
    <emdnCode>W0103080105</emdnCode>
    <emdnDescription>ANTIBODIES FOR SUBTYPING OF LEUKEMIA (EXCEPT B-&amp;T-CELL TYPING)</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>8930085CE</reference>
    <placedOnMarketCountry>Germany</placedOnMarketCountry>
    <lastUpdated>2026-06-30T09:28:13.899Z</lastUpdated>
  </row>
  <row>
    <udiDi>06974501891372</udiDi>
    <basicUdiDi>69745018900C004101W9</basicUdiDi>
    <tradeName>06974501891372</tradeName>
    <deviceName></deviceName>
    <manufacturerName>Agilent Biosciences (Hangzhou) Co., Ltd.</manufacturerName>
    <manufacturerSrn>CN-MF-000013066</manufacturerSrn>
    <authorisedRepresentativeName>Agilent Technologies Denmark ApS</authorisedRepresentativeName>
    <authorisedRepresentativeSrn>DK-AR-000001443</authorisedRepresentativeSrn>
    <riskClass>IVD Sınıf C</riskClass>
    <legislation>UNKNOWN</legislation>
    <emdnCode>W0103080105</emdnCode>
    <emdnDescription>ANTIBODIES FOR SUBTYPING OF LEUKEMIA (EXCEPT B-&amp;T-CELL TYPING)</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>8930277CE</reference>
    <placedOnMarketCountry>Germany</placedOnMarketCountry>
    <lastUpdated>2026-06-30T09:28:11.490Z</lastUpdated>
  </row>
  <row>
    <udiDi>06974501891358</udiDi>
    <basicUdiDi>69745018900C004001W4</basicUdiDi>
    <tradeName>06974501891358</tradeName>
    <deviceName></deviceName>
    <manufacturerName>Agilent Biosciences (Hangzhou) Co., Ltd.</manufacturerName>
    <manufacturerSrn>CN-MF-000013066</manufacturerSrn>
    <authorisedRepresentativeName>Agilent Technologies Denmark ApS</authorisedRepresentativeName>
    <authorisedRepresentativeSrn>DK-AR-000001443</authorisedRepresentativeSrn>
    <riskClass>IVD Sınıf C</riskClass>
    <legislation>UNKNOWN</legislation>
    <emdnCode>W0103080105</emdnCode>
    <emdnDescription>ANTIBODIES FOR SUBTYPING OF LEUKEMIA (EXCEPT B-&amp;T-CELL TYPING)</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>8930037CE</reference>
    <placedOnMarketCountry>Germany</placedOnMarketCountry>
    <lastUpdated>2026-06-30T09:28:09.087Z</lastUpdated>
  </row>
  <row>
    <udiDi>06974501891334</udiDi>
    <basicUdiDi>69745018900C003901XA</basicUdiDi>
    <tradeName>06974501891334</tradeName>
    <deviceName></deviceName>
    <manufacturerName>Agilent Biosciences (Hangzhou) Co., Ltd.</manufacturerName>
    <manufacturerSrn>CN-MF-000013066</manufacturerSrn>
    <authorisedRepresentativeName>Agilent Technologies Denmark ApS</authorisedRepresentativeName>
    <authorisedRepresentativeSrn>DK-AR-000001443</authorisedRepresentativeSrn>
    <riskClass>IVD Sınıf C</riskClass>
    <legislation>UNKNOWN</legislation>
    <emdnCode>W0103080105</emdnCode>
    <emdnDescription>ANTIBODIES FOR SUBTYPING OF LEUKEMIA (EXCEPT B-&amp;T-CELL TYPING)</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>8931035CE</reference>
    <placedOnMarketCountry>Germany</placedOnMarketCountry>
    <lastUpdated>2026-06-30T09:28:06.679Z</lastUpdated>
  </row>
  <row>
    <udiDi>06974501891310</udiDi>
    <basicUdiDi>69745018900C003801X5</basicUdiDi>
    <tradeName>06974501891310</tradeName>
    <deviceName></deviceName>
    <manufacturerName>Agilent Biosciences (Hangzhou) Co., Ltd.</manufacturerName>
    <manufacturerSrn>CN-MF-000013066</manufacturerSrn>
    <authorisedRepresentativeName>Agilent Technologies Denmark ApS</authorisedRepresentativeName>
    <authorisedRepresentativeSrn>DK-AR-000001443</authorisedRepresentativeSrn>
    <riskClass>IVD Sınıf C</riskClass>
    <legislation>UNKNOWN</legislation>
    <emdnCode>W0103080105</emdnCode>
    <emdnDescription>ANTIBODIES FOR SUBTYPING OF LEUKEMIA (EXCEPT B-&amp;T-CELL TYPING)</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>8930132CE</reference>
    <placedOnMarketCountry>Germany</placedOnMarketCountry>
    <lastUpdated>2026-06-30T09:28:03.086Z</lastUpdated>
  </row>
  <row>
    <udiDi>06974501891297</udiDi>
    <basicUdiDi>69745018900C003701WY</basicUdiDi>
    <tradeName>06974501891297</tradeName>
    <deviceName></deviceName>
    <manufacturerName>Agilent Biosciences (Hangzhou) Co., Ltd.</manufacturerName>
    <manufacturerSrn>CN-MF-000013066</manufacturerSrn>
    <authorisedRepresentativeName>Agilent Technologies Denmark ApS</authorisedRepresentativeName>
    <authorisedRepresentativeSrn>DK-AR-000001443</authorisedRepresentativeSrn>
    <riskClass>IVD Sınıf C</riskClass>
    <legislation>UNKNOWN</legislation>
    <emdnCode>W0103080105</emdnCode>
    <emdnDescription>ANTIBODIES FOR SUBTYPING OF LEUKEMIA (EXCEPT B-&amp;T-CELL TYPING)</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>8930268CE</reference>
    <placedOnMarketCountry>Germany</placedOnMarketCountry>
    <lastUpdated>2026-06-30T09:28:00.684Z</lastUpdated>
  </row>
  <row>
    <udiDi>06974501891273</udiDi>
    <basicUdiDi>69745018900C003601WT</basicUdiDi>
    <tradeName>06974501891273</tradeName>
    <deviceName></deviceName>
    <manufacturerName>Agilent Biosciences (Hangzhou) Co., Ltd.</manufacturerName>
    <manufacturerSrn>CN-MF-000013066</manufacturerSrn>
    <authorisedRepresentativeName>Agilent Technologies Denmark ApS</authorisedRepresentativeName>
    <authorisedRepresentativeSrn>DK-AR-000001443</authorisedRepresentativeSrn>
    <riskClass>IVD Sınıf C</riskClass>
    <legislation>UNKNOWN</legislation>
    <emdnCode>W0103080105</emdnCode>
    <emdnDescription>ANTIBODIES FOR SUBTYPING OF LEUKEMIA (EXCEPT B-&amp;T-CELL TYPING)</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>W0103080105</reference>
    <placedOnMarketCountry>Germany</placedOnMarketCountry>
    <lastUpdated>2026-06-30T09:27:58.277Z</lastUpdated>
  </row>
  <row>
    <udiDi>06974501891259</udiDi>
    <basicUdiDi>69745018900C003501WN</basicUdiDi>
    <tradeName>06974501891259</tradeName>
    <deviceName></deviceName>
    <manufacturerName>Agilent Biosciences (Hangzhou) Co., Ltd.</manufacturerName>
    <manufacturerSrn>CN-MF-000013066</manufacturerSrn>
    <authorisedRepresentativeName>Agilent Technologies Denmark ApS</authorisedRepresentativeName>
    <authorisedRepresentativeSrn>DK-AR-000001443</authorisedRepresentativeSrn>
    <riskClass>IVD Sınıf C</riskClass>
    <legislation>UNKNOWN</legislation>
    <emdnCode>W0103080105</emdnCode>
    <emdnDescription>ANTIBODIES FOR SUBTYPING OF LEUKEMIA (EXCEPT B-&amp;T-CELL TYPING)</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>8931032CE</reference>
    <placedOnMarketCountry>Germany</placedOnMarketCountry>
    <lastUpdated>2026-06-30T09:27:55.873Z</lastUpdated>
  </row>
  <row>
    <udiDi>06974501891235</udiDi>
    <basicUdiDi>69745018900C003401WH</basicUdiDi>
    <tradeName>06974501891235</tradeName>
    <deviceName></deviceName>
    <manufacturerName>Agilent Biosciences (Hangzhou) Co., Ltd.</manufacturerName>
    <manufacturerSrn>CN-MF-000013066</manufacturerSrn>
    <authorisedRepresentativeName>Agilent Technologies Denmark ApS</authorisedRepresentativeName>
    <authorisedRepresentativeSrn>DK-AR-000001443</authorisedRepresentativeSrn>
    <riskClass>IVD Sınıf C</riskClass>
    <legislation>UNKNOWN</legislation>
    <emdnCode>W0103080105</emdnCode>
    <emdnDescription>ANTIBODIES FOR SUBTYPING OF LEUKEMIA (EXCEPT B-&amp;T-CELL TYPING)</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>8930216CE</reference>
    <placedOnMarketCountry>Germany</placedOnMarketCountry>
    <lastUpdated>2026-06-30T09:27:53.477Z</lastUpdated>
  </row>
  <row>
    <udiDi>06974501891211</udiDi>
    <basicUdiDi>69745018900C003301WC</basicUdiDi>
    <tradeName>06974501891211</tradeName>
    <deviceName></deviceName>
    <manufacturerName>Agilent Biosciences (Hangzhou) Co., Ltd.</manufacturerName>
    <manufacturerSrn>CN-MF-000013066</manufacturerSrn>
    <authorisedRepresentativeName>Agilent Technologies Denmark ApS</authorisedRepresentativeName>
    <authorisedRepresentativeSrn>DK-AR-000001443</authorisedRepresentativeSrn>
    <riskClass>IVD Sınıf C</riskClass>
    <legislation>UNKNOWN</legislation>
    <emdnCode>W0103080105</emdnCode>
    <emdnDescription>ANTIBODIES FOR SUBTYPING OF LEUKEMIA (EXCEPT B-&amp;T-CELL TYPING)</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>8931013CE</reference>
    <placedOnMarketCountry>Germany</placedOnMarketCountry>
    <lastUpdated>2026-06-30T09:27:51.074Z</lastUpdated>
  </row>
  <row>
    <udiDi>06974501891198</udiDi>
    <basicUdiDi>69745018900C003201W7</basicUdiDi>
    <tradeName>06974501891198</tradeName>
    <deviceName></deviceName>
    <manufacturerName>Agilent Biosciences (Hangzhou) Co., Ltd.</manufacturerName>
    <manufacturerSrn>CN-MF-000013066</manufacturerSrn>
    <authorisedRepresentativeName>Agilent Technologies Denmark ApS</authorisedRepresentativeName>
    <authorisedRepresentativeSrn>DK-AR-000001443</authorisedRepresentativeSrn>
    <riskClass>IVD Sınıf C</riskClass>
    <legislation>UNKNOWN</legislation>
    <emdnCode>W0103080105</emdnCode>
    <emdnDescription>ANTIBODIES FOR SUBTYPING OF LEUKEMIA (EXCEPT B-&amp;T-CELL TYPING)</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>8930264CE</reference>
    <placedOnMarketCountry>Germany</placedOnMarketCountry>
    <lastUpdated>2026-06-30T09:27:48.674Z</lastUpdated>
  </row>
  <row>
    <udiDi>06974501891174</udiDi>
    <basicUdiDi>69745018900C003101W2</basicUdiDi>
    <tradeName>06974501891174</tradeName>
    <deviceName></deviceName>
    <manufacturerName>Agilent Biosciences (Hangzhou) Co., Ltd.</manufacturerName>
    <manufacturerSrn>CN-MF-000013066</manufacturerSrn>
    <authorisedRepresentativeName>Agilent Technologies Denmark ApS</authorisedRepresentativeName>
    <authorisedRepresentativeSrn>DK-AR-000001443</authorisedRepresentativeSrn>
    <riskClass>IVD Sınıf C</riskClass>
    <legislation>UNKNOWN</legislation>
    <emdnCode>W0103080105</emdnCode>
    <emdnDescription>ANTIBODIES FOR SUBTYPING OF LEUKEMIA (EXCEPT B-&amp;T-CELL TYPING)</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>8931049CE</reference>
    <placedOnMarketCountry>Germany</placedOnMarketCountry>
    <lastUpdated>2026-06-30T09:27:45.075Z</lastUpdated>
  </row>
  <row>
    <udiDi>06974501891150</udiDi>
    <basicUdiDi>69745018900C003001VV</basicUdiDi>
    <tradeName>06974501891150</tradeName>
    <deviceName></deviceName>
    <manufacturerName>Agilent Biosciences (Hangzhou) Co., Ltd.</manufacturerName>
    <manufacturerSrn>CN-MF-000013066</manufacturerSrn>
    <authorisedRepresentativeName>Agilent Technologies Denmark ApS</authorisedRepresentativeName>
    <authorisedRepresentativeSrn>DK-AR-000001443</authorisedRepresentativeSrn>
    <riskClass>IVD Sınıf C</riskClass>
    <legislation>UNKNOWN</legislation>
    <emdnCode>W0103080105</emdnCode>
    <emdnDescription>ANTIBODIES FOR SUBTYPING OF LEUKEMIA (EXCEPT B-&amp;T-CELL TYPING)</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>8931036CE</reference>
    <placedOnMarketCountry>Germany</placedOnMarketCountry>
    <lastUpdated>2026-06-30T09:27:42.676Z</lastUpdated>
  </row>
  <row>
    <udiDi>06974501891136</udiDi>
    <basicUdiDi>69745018900C002901X3</basicUdiDi>
    <tradeName>06974501891136</tradeName>
    <deviceName></deviceName>
    <manufacturerName>Agilent Biosciences (Hangzhou) Co., Ltd.</manufacturerName>
    <manufacturerSrn>CN-MF-000013066</manufacturerSrn>
    <authorisedRepresentativeName>Agilent Technologies Denmark ApS</authorisedRepresentativeName>
    <authorisedRepresentativeSrn>DK-AR-000001443</authorisedRepresentativeSrn>
    <riskClass>IVD Sınıf C</riskClass>
    <legislation>UNKNOWN</legislation>
    <emdnCode>W0103080105</emdnCode>
    <emdnDescription>ANTIBODIES FOR SUBTYPING OF LEUKEMIA (EXCEPT B-&amp;T-CELL TYPING)</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>8930265CE</reference>
    <placedOnMarketCountry>Germany</placedOnMarketCountry>
    <lastUpdated>2026-06-30T09:27:40.278Z</lastUpdated>
  </row>
  <row>
    <udiDi>06974501891112</udiDi>
    <basicUdiDi>69745018900C002801WW</basicUdiDi>
    <tradeName>06974501891112</tradeName>
    <deviceName></deviceName>
    <manufacturerName>Agilent Biosciences (Hangzhou) Co., Ltd.</manufacturerName>
    <manufacturerSrn>CN-MF-000013066</manufacturerSrn>
    <authorisedRepresentativeName>Agilent Technologies Denmark ApS</authorisedRepresentativeName>
    <authorisedRepresentativeSrn>DK-AR-000001443</authorisedRepresentativeSrn>
    <riskClass>IVD Sınıf C</riskClass>
    <legislation>UNKNOWN</legislation>
    <emdnCode>W0103080105</emdnCode>
    <emdnDescription>ANTIBODIES FOR SUBTYPING OF LEUKEMIA (EXCEPT B-&amp;T-CELL TYPING)</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>8931034CE</reference>
    <placedOnMarketCountry>Germany</placedOnMarketCountry>
    <lastUpdated>2026-06-30T09:27:37.881Z</lastUpdated>
  </row>
  <row>
    <udiDi>06974501891099</udiDi>
    <basicUdiDi>69745018900C002701WR</basicUdiDi>
    <tradeName>06974501891099</tradeName>
    <deviceName></deviceName>
    <manufacturerName>Agilent Biosciences (Hangzhou) Co., Ltd.</manufacturerName>
    <manufacturerSrn>CN-MF-000013066</manufacturerSrn>
    <authorisedRepresentativeName>Agilent Technologies Denmark ApS</authorisedRepresentativeName>
    <authorisedRepresentativeSrn>DK-AR-000001443</authorisedRepresentativeSrn>
    <riskClass>IVD Sınıf C</riskClass>
    <legislation>UNKNOWN</legislation>
    <emdnCode>W0103080105</emdnCode>
    <emdnDescription>ANTIBODIES FOR SUBTYPING OF LEUKEMIA (EXCEPT B-&amp;T-CELL TYPING)</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>8931033CE</reference>
    <placedOnMarketCountry>Germany</placedOnMarketCountry>
    <lastUpdated>2026-06-30T09:27:35.473Z</lastUpdated>
  </row>
  <row>
    <udiDi>06974501891075</udiDi>
    <basicUdiDi>69745018900C002601WL</basicUdiDi>
    <tradeName>06974501891075</tradeName>
    <deviceName></deviceName>
    <manufacturerName>Agilent Biosciences (Hangzhou) Co., Ltd.</manufacturerName>
    <manufacturerSrn>CN-MF-000013066</manufacturerSrn>
    <authorisedRepresentativeName>Agilent Technologies Denmark ApS</authorisedRepresentativeName>
    <authorisedRepresentativeSrn>DK-AR-000001443</authorisedRepresentativeSrn>
    <riskClass>IVD Sınıf C</riskClass>
    <legislation>UNKNOWN</legislation>
    <emdnCode>W0103080105</emdnCode>
    <emdnDescription>ANTIBODIES FOR SUBTYPING OF LEUKEMIA (EXCEPT B-&amp;T-CELL TYPING)</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>8930263CE</reference>
    <placedOnMarketCountry>Germany</placedOnMarketCountry>
    <lastUpdated>2026-06-30T09:27:33.085Z</lastUpdated>
  </row>
</eudamedExport>